Fibroblast growth factor-2 in hyperplastic pituitaries of D2R knockout female mice

American Journal of Physiology - Endocrinology and Metabolism

Volumn 293, Issue 5, 2007, Pages

  Cristina, Carolina ^a   Díaz Torga, Graciela ^a   Góngora, Adrián ^a   Guida, Maria Clara ^a   Perez Millán, Maria Inés ^a   Baldi, Alberto ^a   Becu Villalobos, Damasia ^a  

^a Universidad Nacional de Río Cuarto Consejo Nacional de Investigaciones Científicas y Técnicas   (Argentina)

Author keywords

Dopaminergic D2 receptor; Extracellular signal regulated kinase phosphorylation; Fibroblast growth factor receptor 1; Immunohistochemistry; Prolactin

Indexed keywords

DOPAMINE 2 RECEPTOR; FIBROBLAST GROWTH FACTOR 2; PROLACTIN;

ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL ASSAY; CELL PROLIFERATION; CELLULAR DISTRIBUTION; CHRONIC DISEASE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CYTOSOL; DNA SYNTHESIS; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME PHOSPHORYLATION; FEMALE; GENOTYPE; HYPERPITUITARISM; HYPERPROLACTINEMIA; HYPOPHYSIS FUNCTION; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; KNOCKOUT MOUSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; PROLACTIN RELEASE; PROLACTINOMA; PROTEIN LOCALIZATION; PROTEIN SECRETION; RELIABILITY; SPECIES COMPARISON; WESTERN BLOTTING; WILD TYPE;

ANIMALS; BLOTTING, WESTERN; CELL GROWTH PROCESSES; ENZYME-LINKED IMMUNOSORBENT ASSAY; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; FIBROBLAST GROWTH FACTOR 2; HYPERPLASIA; IMMUNOHISTOCHEMISTRY; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICROSCOPY, CONFOCAL; MICROSCOPY, FLUORESCENCE; PHOSPHORYLATION; PITUITARY GLAND, ANTERIOR; PROLACTIN; PROLACTINOMA; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 1; RECEPTORS, DOPAMINE D2;

EID: 36148950965     PISSN: 01931849     EISSN: 15221555     Source Type: Journal    
DOI: 10.1152/ajpendo.00260.2007     Document Type: Article

References (57)

1. Abbass SA, Asa SL, Ezzat S. Altered expression of fibroblast growth factor receptors in human pituitary adenomas. J Clin Endocrinol Metab 82: 1160-1166, 1997.
2. Arnaud E, Touriol C, Boutonnet C, Gensac MC, Vagner S, Prats H, Prats AC. A new 34-kilodalton isoform of human fibroblast growth factor 2 is cap dependently synthesized by using a non-AUG start codon and behaves as a survival factor. Mol Cell Biol 19: 505-514, 1999.
3. Asa SL, Kelly MA, Grandy DK, Low MJ. Pituitary lactotroph adenomas develop after prolonged lactotroph hyperplasia in dopamine D2 receptor-deficient mice. Endocrinology 140: 5348-5355, 1999.
4. Baird A, Mormede P, Ying SY, Wehrenberg WB, Ueno N, Ling N, Guillemin R. A nonmitogenic pituitary function of fibroblast growth factor: regulation of thyrotropin and prolactin secretion. Proc Natl Acad Sci USA 82: 5545-5549, 1985.
5. Bikfalvi A, Klein S, Pintucci G, Rifkin DB. Biological roles of fibroblast growth factor-2. Endocr Rev 18: 26-45, 1997.
6. Black EG, Logan A, Davis JR, Sheppard MC. Basic fibroblast growth factor affects DNA synthesis and cell function and activates multiple signalling pathways in rat thyroid FRTL-5 and pituitary GH3 cells. J Endocrinol 127: 39-46, 1990.
7. Choi J, Ko MK, Kay EP. Subcellular localization of the expressed 18 kDa FGF-2 isoform in corneal endothelial cells. Mol Vis 6: 222-231, 2000.
8. Cristina C, Diaz-Torga G, Baldi A, Gongora A, Rubinstein M, Low MJ, Becu-Villalobos D. Increased pituitary vascular endothelial growth factor-A in dopaminergic D2 receptor knockout female mice. Endocrinology 146: 2952-2962, 2005.
9. Cristina C, Diaz-Torga GS, Goya RG, Kakar SS, Perez-Millan MI, Passos VQ, Gianella-Neto D, Bronstein MD, Becu-Villalobos D. PTTG expression in different experimental and human prolactinomas in relation to dopaminergic control of lactotropes. Mol Cancer 6: 4, 2007.
10. Cristina C, García-Tornadú I, Diaz-Torga G, Rubinstein M, Low MJ, Becu-Villalobos D. The dopaminergic D2 receptor knockout mouse: an animal model of prolactinoma. Front Horm Res 35: 50-63, 2006.
11. Delrieu I. The high molecular weight isoforms of basic fibroblast growth factor (FGF-2): an insight into an intracrine mechanism. FEBS Lett 468: 6-10, 2000.
12. Diaz-Torga G, Feierstein C, Libertun C, Gelman D, Kelly MA, Low MJ, Rubinstein M, Becu-Villalobos D. Disruption of the D2 dopamine receptor alters GH and IGF-I secretion and causes dwarfism in male mice. Endocrinology 143: 1270-1279, 2002.
13. Ezzat S, Smyth HS, Ramyar L, Asa SL. Heterogeneous in vivo and in vitro expression of basic fibroblast growth factor by human pituitary adenomas. J Clin Endocrinol Metab 80: 878-884, 1995.
14. Ezzat S, Zheng L, Asa SL. Pituitary tumor-derived fibroblast growth factor receptor 4 isoform disrupts neural cell-adhesion molecule/N-cadherin signaling to diminish cell adhesiveness: a mechanism underlying pituitary neoplasia. Mol Endocrinol 18: 2543-2552, 2004.
15. Ferrara N, Schweigerer L, Neufeld G, Mitchell R, Gospodarowicz D. Pituitary follicular cells produce basic fibroblast growth factor. Proc Natl Acad Sci USA 84: 5773-5777, 1987.
16. Florkiewicz RZ, Baird A, Gonzalez AM. Multiple forms of bFGF: differential nuclear and cell surface localization. Growth Factors 4: 265-275, 1991.
17. Florkiewicz RZ, Majack RA, Buechler RD, Florkiewicz E. Quantitative export of FGF-2 occurs through an alternative, energy-dependent, non-ER/Golgi pathway. J Cell Physiol 162: 388-399, 1995.
18. Fukui S, Otani N, Nawashiro H, Yano A, Nomura N, Miyazawa T, Ohnuki A, Tsuzuki N, Katoh H, Ishihara S, Shima K. Subcellular localization of basic fibroblast growth factor and fibroblast growth factor receptor 1 in pituitary adenomas. Brain Tumor Pathol 19: 23-29, 2002.
19. Fumagalli F, Bedogni F, Maragnoli ME, Gennarelli M, Perez J, Racagni G, Riva MA. Dopaminergic D2 receptor activation modulates FGF-2 gene expression in rat prefrontal cortex and hippocampus. J Neurosci Res 74: 74-80, 2003.
20. Garcia-Tornadu I, Rubinstein M, Gaylinn BD, Hill D, Arany E, Low MJ, Diaz-Torga G, Becu-Villalobos D. GH in the dwarf dopaminergic D2 receptor knockout mouse: somatotrope population, GH release, and responsiveness to GH-releasing factors and somatostatin. J Endocrinol 190: 611-619, 2006.
21. Gonzalez AM, Logan A, Ying W, Lappi DA, Berry M, Baird A. Fibroblast growth factor in the hypothalamic-pituitary axis: differential expression of fibroblast growth factor-2 and a high affinity receptor. Endocrinology 134: 2289-2297, 1994.
22. Gonzalez Iglesias A, Diaz-Torga G, Piroli G, Achaval-Zaia R, De Nicola AF, Libertun C, Becu-Villalobos D. Bromocriptine restores Angiotensin II response in pituitary hyperplasia. Mol Cell Endocrinol 165: 67-74, 2000.
23. Gospodarowicz D, Cheng J, Lui GM, Baird A, Bohlen P. Isolation of brain fibroblast growth factor by heparin-Sepharose affinity chromatography: identity with pituitary fibroblast growth factor. Proc Natl Acad Sci USA 81: 6963-6967, 1984.
24. Gospodarowicz D, Ferrara N, Schweigerer L, Neufeld G. Characterization and biological functions of fibroblast growth factors. Endocr Rev 8: 95-114, 1987.
25. Graeven U, Fiedler W, Karpinski S, Ergun S, Kilic N, Rodeck U, Schmiegel W, Hossfeld DK. Melanoma-associated expression of vascular endothelial growth factor and its receptors FLT-1 and KDR. J Cancer Res Clin Oncol 125: 621-629, 1999.
26. Heaney AP, Fernando M, Melmed S. Functional role of estrogen in pituitary tumor pathogenesis. J Clin Invest 109: 277-283, 2002.
27. Heaney AP, Horwitz GA, Wang Z, Singson R, Melmed S. Early involvement of estrogen-induced pituitary tumor transforming gene and fibroblast growth factor expression in prolactinoma pathogenesis. Nat Med 5: 1317-1321, 1999.
28. Iaccarino C, Samad TA, Mathis C, Kercret H, Picetti R, Borrelli E. Control of lactotrop proliferation by dopamine: essential role of signaling through D2 receptors and ERKs. Proc Natl Acad Sci USA 99: 14530-14535, 2002.
29. Ishikawa H, Heaney AP, Yu R, Horwitz GA, Melmed S. Human pituitary tumor-transforming gene induces angiogenesis. J Clin Endocrinol Metab 86: 867-874, 2001.
30. Joy A, Moffett J, Neary K, Mordechai E, Stachowiak EK, Coons S, Rankin-Shapiro J, Florkiewicz RZ, Stachowiak MK. Nuclear accumulation of FGF-2 is associated with proliferation of human astrocytes and glioma cells. Oncogene 14: 171-183, 1997.
31. Kelly MA, Rubinstein M, Asa SL, Zhang G, Saez C, Bunzow JR, Allen RG, Hnasko R, Ben-Jonathan N, Grandy DK, Low MJ. Pituitary lactotroph hyperplasia and chronic hyperprolactinemia in dopamine D2 receptor-deficient mice. Neuron 19: 103-113, 1997.
32. Keresztes M, Boonstra J. Import(ance) of growth factors in(to) the nucleus. J Cell Biol 145: 421-424, 1999.
33. Kuchenbauer F, Theodoropoulou M, Hopfner U, Stalla J, Renner U, Tonn JC, Low MJ, Arzt E, Stalla GK, Paez-Pereda M. Laminin inhibits lactotroph proliferation and is reduced in early prolactinoma development. Mol Cell Endocrinol 207: 13-20, 2003.
34. Larson GH, Koos RD, Sortino MA, Wise PM. Acute effect of basic fibroblast growth factor on secretion of prolactin as assessed by the reverse hemolytic plaque assay. Endocrinology 126: 927-932, 1990.
35. Li A, Guo H, Luo X, Sheng J, Yang S, Yin Y, Zhou J, Zhou J. Apomorphine-induced activation of dopamine receptors modulates FGF-2 expression in astrocytic cultures and promotes survival of dopaminergic neurons. FASEB J 20: 1263-1265, 2006.
36. Li Y, Koga M, Kasayama S, Matsumoto K, Arita N, Hayakawa T, Sato B. Identification and characterization of high molecular weight forms of basic fibroblast growth factor in human pituitary adenomas. J Clin Endocrinol Metab 75: 1436-1441, 1992.
37. Marin F, Boya J. Immunocytochemical localization of basic fibroblast growth factor in the human pituitary gland. Neuroendocrinology 62: 523-529, 1995.
38. McCabe CJ, Khaira JS, Boelaert K, Heaney AP, Tannahill LA, Hussain S, Mitchell R, Olliff J, Sheppard MC, Franklyn JA, Gittoes NJ. Expression of pituitary tumour transforming gene (PTTG) and fibroblast growth factor-2 (FGF-2) in human pituitary adenomas: relationships to clinical tumour behaviour. Clin Endocrinol (Oxf) 58: 141-150, 2003.
39. Meloche S, Seuwen K, Pages G, Pouyssegur J. Biphasic and synergistic activation of p44mapk (ERK1) by growth factors: correlation between late phase activation and mitogenicity. Mol Endocrinol 6: 845-854, 1992.
40. Mormede P, Baird A. Estrogens, cyclic adenosine 3-′,5′-monophosphate, and phorbol esters modulate the prolactin response of GH3 cells to basic fibroblast growth factor. Endocrinology 122: 2265-2271, 1988.
41. Moscatelli D. High and low affinity binding sites for basic fibroblast growth factor on cultured cells: absence of a role for low affinity binding in the stimulation of plasminogen activator production by bovine capillary endothelial cells. J Cell Physiol 131: 123-130, 1987.
42. Moscatelli D. Autocrine downregulation of fibroblast growth factor receptors in F9 teratocarcinoma cells. J Cell Physiol 160: 555-562, 1994.
43. Mukdsi JH, De Paul AL, Petiti JP, Gutierrez S, Aoki A, Torres AI. Pattern of FGF-2 isoform expression correlated with its biological action in experimental prolactinomas. Acta Neuropathol (Berl) 112: 491-501, 2006.
44. Okada-Ban M, Thiery JP, Jouanneau J. Fibroblast growth factor-2. Int J Biochem Cell Biol 32: 263-267, 2000.
45. Piroli G, Torres A, Grillo C, Lux-Lantos V, Aoki A, De Nicola AF. Mechanisms in progestin antagonism of pituitary tumorigenesis. J Steroid Biochem Mol Biol 64: 59-67, 1998.
46. Presta M, Dell'Era P, Mitola S, Moroni E, Ronca R, Rusnati M. Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. Cytokine Growth Factor Rev 16: 159-178, 2005.
47. Renko M, Quarto N, Morimoto T, Rifkin DB. Nuclear and cytoplasmic localization of different basic fibroblast growth factor species. J Cell Physiol 144: 108-114, 1990.
48. Roceri M, Molteni R, Fumagalli F, Racagni G, Gennarelli M, Corsini G, Maggio R, Riva M. Stimulatory role of dopamine on fibroblast growth factor-2 expression in rat striatum. J Neurochem 76: 990-997, 2001.
49. Saiardi A, Bozzi Y, Baik JH, Borrelli E. Antiproliferative role of dopamine: loss of D2 receptors causes hormonal dysfunction and pituitary hyperplasia. Neuron 19: 115-126, 1997.
50. Schechter J, Weiner R. Changes in basic fibroblast growth factor coincident with estradiol-induced hyperplasia of the anterior pituitaries of Fischer 344 and Sprague-Dawley rats. Endocrinology 129: 2400-2408, 1991.
51. Silverlight JJ, Prysor-Jones RA, Jenkins JS. Basic fibroblast growth factor in human pituitary tumors. Clin Endocrinol (Oxf) 32: 669-676, 1990.
52. Straume O, Akslen LA. Importance of vascular phenotype by basic fibroblast growth factor, and influence of the angiogenic factors basic fibroblast growth factor/fibroblast growth factor receptor-1 and ephrin-A1/ EphA2 on melanoma progression. Am J Pathol 160: 1009-1019, 2002.
53. Strauss O, Mergler S, Wiederholt M. Regulation of L-type calcium channels by protein tyrosine kinase and protein kinase C in cultured rat and human retinal pigment epithelial cells. FASEB J 11: 859-867, 1997.
54. Sulpice E, Bryckaert M, Lacour J, Contreres JO, Tobelem G. Platelet factor 4 inhibits FGF2-induced endothelial cell proliferation via the extracellular signal-regulated kinase pathway but not by the phosphatidyl-inositol 3-kinase pathway. Blood 100: 3087-3094, 2002.
55. Tfelt-Hansen J, Kanuparthi D, Chattopadhyay N. The emerging role of pituitary tumor transforming gene in tumorigenesis. Clin Med Res 4: 130-137, 2006.
56. Tooyama I, Kawamata T, Walker D, Yamada T, Hanai K, Kimura H, Iwane M, Igarashi K, McGeer EG, McGeer PL. Loss of basic fibroblast growth factor in substantia nigra neurons in Parkinson's disease. Neurology 43: 372-376, 1993.
57. Zhang X, Horwitz GA, Prezant TR, Valentini A, Nakashima M, Bronstein MD, Melmed S. Structure, expression, and function of human pituitary tumor-transforming gene (PTTG). Mol Endocrinol 13: 156-166, 1999.